Interview with Willem Dekker , Regional Director, Nycomed Australia
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
Address: 2-4 Lyonpark Road,MACQUARIE PARK NSW 2113,Australia
Tel: 61 (02) 9859 6900
Web: http://www.takedaaustralia.com.au/au/
Building valued partnerships with the medical professionals who prescribe and recommend our products is both Nycomed Australia’s greatest challenge and our greatest reward. These aspirations as well as our commitment to provide medicines that offer real promise to patients, drives us to seek innovative and efficient ways of presenting our products to the Australian market.
Through a commitment to the ethical and professional delivery of quality medical education, Nycomed Australia is continually building valued relationships with the medical community. This is achieved by the creation of focused disease state education programs, and the facilitation of knowledge sharing between thought leaders and primary care practitioners. While Nycomed Australia always strive to keep Somac® (pantoprazole) and Alvesco ® (ciclesonide) at the ‘top of the mind’ of Australian prescribers, activities are often unrelated to their products and instead focus on topics of clearly identified educational needs within the areas of Gastroenterology and Respiratory Medicine.
In addition to building relationships with individual healthcare professionals, Nycomed Australia seeks to develop productive partnerships with the peak bodies that share our therapeutic focus. For example, The Gastroenterology Society of Australia guides us in the field of gastroenterology. In the area of respiratory medicine, Nycomed Australia has developed positive relationships with both the National Asthma Council and the Australian Lung Foundation. Nycomed Australia is also excited by the prospect of pioneering new relationships with peak bodies in emerging areas of therapeutic interest.
As a member of Medicines Australia, Nycomed Australia is devoted to strengthening the pharmaceutical industry’s position as a partner in quality healthcare delivery. This is achieved through the ethical promotion of our products and our support of the Medicines Australia code of conduct. Nycomed and its people are proud of their contribution to the Australian healthcare environment and seek to ensure that their organisation acts as a trusted pharmaceutical partner.
Every day across Australia, our highly trained industry-accredited representatives bring life to our products and services. They are the face of Nycomed Australia.
Nycomed Australia’s professional team is committed to our vision to become the preferred pharmaceutical company by being responsive, reliable and by understanding customer needs.
Gastroenterology and Respiratory Medicine
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
Pharma in 2026 will be defined by unpredictability. Executives are already being pushed by shifting policy, commercial, and scientific forces into making fast and tough strategic choices, with more to…
Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the…
A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean…
Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.…
In his latest opinion piece, Shawview Consulting’s Brendan Shaw draws from classic sci-fi to reflect on the pros and cons of using artificial intelligence for health technology assessment. Shaw concludes…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
See our Cookie Privacy Policy Here